Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-06-07
1998-05-05
Ketter, James
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
424450, 536 2431, 536 2433, 536 245, A01N 4304
Patent
active
057474702
ABSTRACT:
The present invention relates to methods of treating disease-associated cellular proliferation using oligonucleotides. In particular, it relates to the use of oligonulceotides which are substantially complementary to gp13O mRNA sequences. In the form of pharmaceutical compositions, these oligonucleotides are suitable for administration to human subjects for the treatment of abnormal cellular proliferation due to such diseases as cancer, autoimmune disorders and viral infection.
REFERENCES:
patent: 5252723 (1993-10-01), Bhatt
Bangham, et al. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Med. Biol. 13:238-252 (1965).
Caruthers, et al. Chemical synthesis of deoxyoligonucleotides by the phosphoramidite method. Methods in Enzymology 154:287-313 Academic Press, Inc. (1987).
Girasole, et al. Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteobdlasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. The Journal of Clinical Investigation, Inc. 89:883-891 (1992).
Grossman, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc. Natl. Acad. Sci. 86:6367-6371. Medical Sciences U.S.A. (1989).
Hibi, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63:1149-1157 Cell Press (1990).
Jilka, et al. Increased osteoclast development after estrogel loss: mediation by interleukin-6. Science 257:88-91 (1992).
Kishimoto, et al. Interleukin-6 and its receptor: A paradigm for cytokines. Science 258:593-597. (1992).
Klein, et al. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur. Cytokine Net. 1:193-201 (1990).
Levy, et al. Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J. Clin. Invest. 88:696-699. (1991).
Majumdar, et al. Stepwise mechanism of HIV reverse transcriptase: Primer function of phosphorothioate oligodeoxynucleotide. Biochemistry. 28:1340-1346. American Chemical Society (1989).
Miles, et al. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc. Natl. Acad. Sci. 87:4068-4072. Medical Sciences, U.S.A. (1990).
Milligan, et al. Development of antisense therapeutics. Implications for cancer gene therapy. Annals New York Academy of Sciences. 716:228-241 (1994).
Nishimoto, et al. Oncostatin M, Leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, GP130. J. Exp. Med. 179:1343-1347. The Rockefeller University Press (1994).
Scala, et al. Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. J. Exp. Med. 172:61-68. The Rockefeller University Press (1990).
Shuin, et al. The activity of topoisomerases is related to the grade and stage in human renal cell carcinoma. AntiCancer Research. 14:2621-2626. (1994).
Stec, et al. Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides. J. Am. Chem. Soc. 106:6077-6079 American Chemical Society (1984).
Stein, et al. Phosphorthioate oligodeoxynucleotides anti-sense inhibitors of gene expression. Pharmac. Ther. 52:365-384. Pergamon Press Ltd., Great Britian (1992).
Takenawa, et al. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. Journal of the National Cancer Institute. 83:1668-1672 (1991).
Vink, et al. Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor. J. Exp. Med. 172:997-1000. The Rockefeller University Press, (1990).
Uhlmann, et al., "Antisense Oligonucleotides: A New Therapeutic Principle", Chemical Reviews, 90(4):543-584, (Jun. 1990).
Hibi, et al. Dec. 21, 1990. Cell 63:1149-57. Molecular Cloning and expression of an IL-6 Signal Transducer, gp130.
Liu, et al. 1992. J. Biol. Chem. 267(24):16763-16766. Interleukin-6 Signal Transducer gp130 Mediates Oncostatin M Signaling.
Felgner, et al. 1987. PNAS. 84:7413-7417. Lipofection: A Highly efficient lipid-mediated DNA -transfection procedure.
Milligan, et al. 1994. Annals of New York Academy of Sciences. 716:228-241. Development of Antisense Therapeutics.
Gura, T. Oct. 27, 1995. Science. 270:575-577. Antisense has Growing Pains.
Gupta, et al., "Silencing of gp130 Gene Expression By Antisense Ribozyme Technology Blocks CNTF Signal Transduction In Embryonal Carcinoma Cells", Society For Neuroscience Abstracts, 19(1-3), (1993).
Becherer Kathleen
Dattagupta Nanibhushan
Naidu Yathi M.
Cappellari Charles B.
Fisher Carlos A.
Gen-Probe Incorporated
Ketter James
Yucel Irem
LandOfFree
Method for inhibiting cellular proliferation using antisense oli does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting cellular proliferation using antisense oli, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting cellular proliferation using antisense oli will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-54694